[Skip to Content]
[Skip to Content Landing]
June 23/30, 2004

Obesity and Erectile DysfunctionCommon Problems, Common Solution?

Author Affiliations

Author Affiliation: Department of Urology, University of California, Los Angeles.

JAMA. 2004;291(24):3011-3012. doi:10.1001/jama.291.24.3011

The introduction of sildenafil (Viagra) in 1998 unleashed a tidal wave of interest in medical treatment for erectile dysfunction (ED). Although data from the Massachusetts Male Aging Study indicated that approximately 52% of men aged 40 to 70 years experienced some degree of ED,1 many of these men were either unaware of treatment options for the condition, averse to the invasive nature of some of the existing options, or too embarrassed to discuss the topic with a physician. The heavy direct-to-consumer marketing campaign that accompanied the release of this drug contributed to a new, open discussion in popular culture about this highly prevalent condition; ED was suddenly fair game for late night comics and national news magazine covers. By the end of 1999, Viagra was a billion-dollar drug.2 From 1996 to 2000, the national rate of physician office visits during which ED was one of the reasons for the encounter increased by almost 50%.3

First Page Preview View Large
First page PDF preview
First page PDF preview